A regulatory variant at 19p13.3 is associated with primary biliary cholangitis risk and ARID3A expression
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index; 11 of the 42 sources its claims cite were checked for support.
Abstract
Genome-wide association studies have identified 19p13.3 locus associated with primary biliary cholangitis (PBC). Here we aim to identify causative variant(s) and initiate efforts to define the mechanism by which the 19p13.3 locus variant(s) contributes to the pathogenesis of PBC. A genome-wide meta-analysis of 1931 PBC subjects and 7852 controls in two Han Chinese cohorts confirms the strong association between 19p13.3 locus and PBC. By integrating functional annotations, luciferase reporter assay and allele-specific chromatin immunoprecipitation, we prioritize rs2238574, an AT-Rich Interaction Domain 3A (ARID3A) intronic variant, as a potential causal variant at 19p13.3 locus. The risk allele of rs2238574 shows higher binding affinity of transcription factors, leading to an increased enhancer activity in myeloid cells. Genome-editing demonstrates the regulatory effect of rs2238574 on ARID3A expression through allele-specific enhancer activity. Furthermore, knock-down of ARID3A inhibits myeloid differentiation and activation pathway, and overexpression of the gene has the opposite effect. Finally, we find ARID3A expression and rs2238574 genotypes linked to disease severity in PBC. Our work provides several lines of evidence that a non-coding variant regulates ARID3A expression, presenting a mechanistic basis for association of 19p13.3 locus with the susceptibility to PBC.
Overview
CoChat Summary
TL;DR
A genome-wide meta-analysis in Han Chinese cohorts confirms the 19p13.3 locus in primary biliary cholangitis (PBC), and functional work prioritizes the ARID3A intronic variant rs2238574 as a likely causal regulatory SNP. The risk allele increases enhancer activity and transcription factor binding, upregulates ARID3A in myeloid cells, and is linked to PBC disease severity.
Key findings
- Meta-analysis of 1,931 PBC subjects and 7,852 controls confirmed strong association at 19p13.3 (rs2238571: OR = 0.77, p = 5.24 × 10−10), with no secondary signal after conditional analysis.
- rs2238574, an ARID3A intronic variant, was prioritized: its risk allele showed higher enhancer activity in HEK293T and K562 cells, and allele-specific ChIP showed preferential binding of PPARG, NR2F1, and NR2C2 to the risk allele in K562 cells and primary human CD14+ monocytes.
- CRISPR/Cas9-edited K562 cells with C/C genotype had increased ARID3A expression, higher PPARG/NR2F1/NR2C2 occupancy, lower CD117, and higher CD33 than A/A cells; ARID3A knockdown downregulated myeloid differentiation/activation pathways and reduced BATF2/SPI1, while overexpression increased BATF2/SPI1.
- In PBC, hepatic ARID3A-positive inflammatory cells correlated with inflammation grade (r = 0.6811, p < 0.001), fibrosis stage (r = 0.4793, p < 0.001), AST (r = 0.3245, p = 0.0035), ALP (r = 0.3007, p = 0.0067), GGT (r = 0.3608, p = 0.0010), and IgM (r = 0.2841, p = 0.0117); the rs2238574 C risk allele was associated with higher liver fibrosis stage after correcting for disease history, but not with inflammation grade.
Methods
- Two independent Han Chinese PBC cohorts were genotyped and meta-analyzed: cohort 1 had 1,121 cases and 5,467 controls; cohort 2 had 820 cases and 3,194 controls, yielding 1,931 cases and 7,852 controls after quality control. Imputation used 1000 Genomes phase 3, and association used logistic regression with age, sex, and ten principal components, followed by inverse-variance fixed-effects meta-analysis.
- Functional annotation integrated Haploreg, rSNPBase, RegulomeDB, ENCODE, GTEx eQTL, and Hi-C data. Candidate variant effects were tested by luciferase enhancer reporter assays, ChIP-qPCR, allele-specific ChIP-qPCR, Sanger sequencing, and CRISPR/Cas9 prime editing in K562 cells.
- ARID3A function was studied by lentiviral shRNA knockdown and overexpression in K562 cells, RNA-seq/GSEA, qPCR, flow cytometry for CD33/CD117/CD68, and monocyte-derived macrophages. Clinical analyses used liver biopsies from 89 PBC, 42 AIH, 20 CHB, and 10 healthy controls, plus whole-blood transcriptome data from 90 PBC and 47 healthy controls.
Limitations
- The paper states that additional variants at this locus may also affect disease phenotype, and it cannot exclude additional or alternate causal hypotheses.
- The paper states that functional relevance of 19p13.3 and ARID3A was investigated only in a limited number of clinical samples, and larger sample sizes are needed for clinical correlations.
- The paper states that genetically engineered mouse models are warranted to further explore the role of ARID3A variants in PBC; evident from the text, the mechanistic work relies heavily on cell lines and in vitro assays, with limited in vivo validation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
5 Valid · 3 Not valid · 15 Not checked · 57 Own results and interpretations
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“We observed an enrichment of epigenetic marks for active enhancers at rs2238574-containing region in human CD14+ monocytes (Supplementary Fig. 3A).”
§ A regulatory variant at 19p13.3 is associated with primary biliary cholangitis risk and ARID3A expression > Results > Rs2238574 affects transcription factor binding
What the sources say
- Could not verifycites [14] Consortium, E. P. An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57–74 (2012). sourceExperimental — accuracy not yet measured
Our copy of the ENCODE 2012 paper contains no mention of rs2238574 (searched by rsID directly) and no locus-level statement about an active-enhancer signature at that region; the allele-specific and common-variant sections ('Insights into human genomic variation', 'Common variants associated with human disease and phenotypes') discuss only GM12878/NA12878 examples and GWAS-SNP enrichment statistics (e.g., Crohn's SNPs at 5p13.1 in Th1/Th2 DHSs). The paper does define active-enhancer marks (H3K4me1 with H3K27ac, 'Genome-wide integration') and profiles histone modifications in 46 cell types and DNase-seq in 125 cell types ('Regions of histone modifications'; 'DNaseI hypersensitive sites...'), but no passage names CD14+ monocytes or reports the attributed enrichment. Nothing in our copy contradicts the claim, so the specific observation (the citing authors' own Supplementary Fig. 3A analysis) cannot be checked here. (LLM, conf=0.70)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Recent scRNA-seq data also revealed that ARID3A was highly expressed in myeloid cells, especially mature myeloid cells18,19.”
§ A regulatory variant at 19p13.3 is associated with primary biliary cholangitis risk and ARID3A expression > Discussion
What the sources say
- Could not verifycites [18] Xie, X. et al. Single-cell transcriptomic landscape of human blood cells. Natl. Sci. Rev. 8, nwaa180 (2021). sourceExperimental — accuracy not yet measured
The Results sections on hematopoietic cell populations and regulatory networks describe myeloid cells and name other highly expressed genes, but do not report ARID3A expression. Searches for “ARID3A” and “mature myeloid cells ARID3A” found no passage establishing the claimed pattern. Page numbers were not available in our copy. (LLM, conf=0.73)
- Could not verifycites [19] Bagger, F. O., Kinalis, S. & Rapin, N. BloodSpot: a database of healthy and malignant haematopoiesis updated with purified and single cell mRNA sequencing profiles. Nucleic Acids Res. 47, D881–D885 (2019). sourceExperimental — accuracy not yet measured
The Results and Discussion section describes single-cell haematopoietic expression datasets and their visualization, but does not report ARID3A expression by cell type. Searches for ARID3A and for the claimed myeloid-cell expression pattern found no passage establishing that it is especially high in mature myeloid cells. (LLM, conf=0.76)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Myeloid cells, i.e., monocytes and macrophages, represent a key component of innate and adaptive immune systems and play an important role in the pathogenesis of PBC.”
§ A regulatory variant at 19p13.3 is associated with primary biliary cholangitis risk and ARID3A expression > Discussion
What the sources say
- Supportedcites [34] Shimoda, S. et al. CX3CL1 (fractalkine): a signpost for biliary inflammation in primary biliary cirrhosis. Hepatology 51, 567–575 (2010). source
The Results (‘Monocytes around BEC in the liver’) report enrichment of CD68+ monocytes/macrophages around bile ducts in PBC. The Results (‘BEC pre-treated with Poly I:C…’) show that stimulated monocytes supplied the contact and TNF-α needed for biliary epithelial cells to produce CX3CL1; the Abstract links this pathway to lymphocyte recruitment and characteristic biliary inflammation in PBC. (LLM, conf=0.90)
- Not checked yetcites [35] Mao, T. K. et al. Altered monocyte responses to defined TLR ligands in patients with primary biliary cirrhosis. Hepatology 42, 802–808 (2005). source
- Not checked yetcites [36] Yan, C. et al. Roles of trained immunity in the pathogenesis of cholangiopathies: a therapeutic target. Hepatology 72, 1838–1850 (2020). source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“We recently performed a large-scale GWAS in a Han Chinese PBC cohort and identified six novel variants associated with PBC, in which we first reported that the 19p13.3 locus was associated with PBC13.”
§ A regulatory variant at 19p13.3 is associated with primary biliary cholangitis risk and ARID3A expression > Introduction
What the sources say
- Partly supportedcites [13] Qiu, F. et al. A genome-wide association study identifies six novel risk loci for primary biliary cholangitis. Nat. Commun. 8, 14828 (2017). sourceExperimental — accuracy not yet measured
The Results (Discovery and validation of six novel PBC risk loci; page unavailable) report a newly validated association between the ARID3A locus and PBC in the study’s Han Chinese cohort, and describe it as the first reported association of that locus with human autoimmune or inflammatory disease. The passages in our copy do not identify ARID3A as 19p13.3, so they do not verify the claim’s specific chromosomal designation. (LLM, conf=0.82)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“The results showed a marginal but significant increase in ARID3A expression in whole blood cells from PBC compared to HCs (Fig. 6C).”
§ A regulatory variant at 19p13.3 is associated with primary biliary cholangitis risk and ARID3A expression > Results > Increased ARID3A expression in PBC
What the sources say
- Could not verifycites [20] Ostrowski, J. et al. Common functional alterations identified in blood transcriptome of autoimmune cholestatic liver and inflammatory bowel diseases. Sci. Rep. 9, 7190 (2019). sourceExperimental — accuracy not yet measured
Our copy of Ostrowski et al. 2019 nowhere mentions ARID3A (searched: 'ARID3A', 'AT-rich interaction domain transcription factor chromatin binding gene PBC upregulated'). The Results section 'Expression of genes selected for potential use in diagnostic screening' and Table 4 list the 13 PBC-selected genes (EMR1, IFI27, PLCB2, RARA, SORL, STAT1, ABCG1, C15orf39, LYN, PLEKHG3, ATG2, MME, DEFA1) and the 7 confirmed by qRT-PCR (EMR1, IFI27, PLCB2, RARA, STAT1, ABCG1, C15orf39), none of which is ARID3A, so the paper reports no ARID3A measurement in PBC versus healthy controls. Since the paper does not address ARID3A at all, its copy neither supports nor contradicts the attributed finding. (LLM, conf=0.70)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
45 more claims
Create a free account to see all 80 claims and to verify the 31 references still open.
- It may state two separate claims as one. 17
- Probably not a substantial claim. 20
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Notably, a non-coding causal variant in the 19p13.3locus controls expression of ARID3A, leading to dysregulated myeloid cell differentiation and function.20”
From Primary biliary cholangitis. (2024) · cites this paper as [20]
Experimental — accuracy not yet measuredIn the citing paper
“Importantly, variants in the 19p13.3 locus were shown to play a role in PBC pathogenesis in two Chinese cohorts through increased autophagy-related ARID3A enhancer activity in CD14+ monocytes [182].”
From Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells (2025) · doi:10.1038/s41423-025-01313-7 · cites this paper as [182]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A regulatory variant at 19p13.3 is associated with primary biliary cholangitis risk and ARID3A expression > Discussion
“We found that transcription factors including PPARG, NR2G1 and NR2C2, preferentially bound the risk allele of rs2238574, which led to increased expression of ARID3A.”
§ A regulatory variant at 19p13.3 is associated with primary biliary cholangitis risk and ARID3A expression > Results > Rs2238574 affects transcription factor binding
“Strikingly, the risk-associated C allele of rs2238574 exhibited a higher binding affinity for PPARG, NR2F1 and NR2C2 relative to that of the non-risk allele.”
Citations
Cites
A global reference for human genetic variation
The 1000 Genomes Project Consortium, authors, C., Auton, A., Abecasis, G. R., Steering committee, Altshuler, D. M., Durbin, R. M., Abecasis, G. R., Bentley, D. R., Chakravarti, A., et al. (2015) · Nature · doi:10.1038/nature15393 · Cited by 18,247
Self-citationAn integrated encyclopedia of DNA elements in the human genome
The ENCODE Project Consortium (2012) · Nature · doi:10.1038/nature11247 · Cited by 18,072
Self-citationSzklarczyk, D., Morris, J. H., Cook, H., Kuhn, M., Wyder, S., Simonovic, M., Santos, A., Doncheva, N. T., Roth, A., Bork, P., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw937 · Cited by 6,980
The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans
The GTEx Consortium, Ardlie, K. G., Deluca, D. S., Segrè, A. V., Sullivan, T. J., Young, T. R., Gelfand, E. T., Trowbridge, C. A., Maller, J. B., Tukiainen, T., et al. (2015) · Science · doi:10.1126/science.1262110 · Cited by 5,062
Search-and-replace genome editing without double-strand breaks or donor DNA
Anzalone, A. V., Randolph, P. B., Davis, J. R., Sousa, A. A., Koblan, L. W., Levy, J. M., Chen, P. J., Wilson, C., Newby, G. A., Raguram, A., et al. (2019) · Nature · doi:10.1038/s41586-019-1711-4 · Cited by 4,767
Howie, B. N., Donnelly, P., & Marchini, J. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000529 · Cited by 3,928
Annotation of functional variation in personal genomes using RegulomeDB
Boyle, A. P., Hong, E. L., Hariharan, M., Cheng, Y., Schaub, M. A., Kasowski, M., Karczewski, K. J., Park, J., Hitz, B. C., Weng, S., et al. (2012) · Genome Research · doi:10.1101/gr.137323.112 · Cited by 2,722
LocusZoom: regional visualization of genome-wide association scan results
Pruim, R. J., Welch, R. P., Sanna, S., Teslovich, T. M., Chines, P. S., Gliedt, T. P., Boehnke, M., Abecasis, G. R., & Willer, C. J. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq419 · Cited by 2,707
Ward, L. D., & Kellis, M. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr917 · Cited by 2,229
CHOPCHOP v3: expanding the CRISPR web toolbox beyond genome editing
Labun, K., Montague, T. G., Krause, M., Torres Cleuren, Y. N., Tjeldnes, H., & Valen, E. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz365 · Cited by 2,054
Cited by
Tanaka, A., Ma, X., Takahashi, A., & Vierling, J. M. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01303-5 · Cited by 177
Self-citation(2025) · doi:10.1038/s41423-025-01313-7 · Cited by 97
A+T rich interaction domain protein 3a (Arid3a) impairs Mertk-mediated efferocytosis in cholestasis
Chen, R., Huang, B., Lian, M., Wei, Y., Miao, Q., Liang, J., Ou, Y., Liang, X., Zhang, H., Li, Y., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.08.016 · Cited by 39
Self-citationExploring noncoding variants in genetic diseases: from detection to functional insights
Wu, K., Bu, F., Wu, Y., Zhang, G., Wang, X., He, S., Liu, M., Chen, R., & Yuan, H. (2024) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2024.01.001 · Cited by 41
Self-citationThe immunological landscape of primary biliary cholangitis: Mechanisms and therapeutic prospects
Ronca, V., Davies, S. P., Oo, Y. H., & Lleo, A. (2025) · Hepatology · doi:10.1097/hep.0000000000001225 · Cited by 22
Metadata
- Authors
- Li, Y., Li, Z., Chen, R., Lian, M., Wang, H., Wei, Y., You, Z., Zhang, J., Li, B., Li, Y., Huang, B., Chen, Y., Liu, Q., Lyu, Z., Liang, X., Miao, Q., Xiao, X., Wang, Q., Fang, J., Shi, Y., Liu, X., Seldin, M. F., Gershwin, M. E., Tang, R., & Ma, X.
- Affiliations
- Shanghai Jiao Tong University (CN)
- Qingdao University (CN)
- Southeast University (CN)
- University of California, Davis (US)
- Corresponding author
- Gershwin, M. Eric
- Tang, Ruqi
- Ma, Xiong
- ORCID
- Venue
- Nature Communications
- Published
- 2023-03-28
- Volume
- 14
- Issue
- 1
- Pages
- 1732-1732
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC10049997
- OpenAlex
- W4361216327
- Cited by
- 18
- References
- 56
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 7 · 2023: 4
- FWCI
- 0.78
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (81922010, 82070583, 81873561, 81570469, 81830016, 81620108002, 81922010, 81873561 and 81570469, 81771732, 81800504)
- Shanghai Education Development Foundation (20XD1422500)
- Shanghai Municipal Education Commission
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- primary biliary cirrhosis, ARID3A, regulatory variants, non-coding variants, enhancer activity, transcription factor binding, myeloid cells, disease susceptibility, disease severity, Han Chinese
- MeSH terms
- DNA-Binding Proteins, Genotype, Humans, Liver Cirrhosis, Biliary, Transcription Factors, Genetic Predisposition to Disease, Genome-Wide Association Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A regulatory variant at 19p13.3 is associated with primary biliary cholangitis risk and ARID3A expression. https://app.cochat.ai/papers/10.1038/s41467-023-37213-5
- The paper
- Li, Y., Li, Z., Chen, R., Lian, M., Wang, H., Wei, Y., You, Z., Zhang, J., Li, B., Li, Y., Huang, B., Chen, Y., Liu, Q., Lyu, Z., Liang, X., Miao, Q., Xiao, X., Wang, Q., Fang, J., . . . Ma, X. (2023). A regulatory variant at 19p13.3 is associated with primary biliary cholangitis risk and ARID3A expression. Nature Communications. https://doi.org/10.1038/s41467-023-37213-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.